Ten-year users of Slim Fast meal replacement products experienced a 33-pound greater reduction compared to non-users, George Blackburn, MD, Beth Israel Deaconess Hospital, Boston, et al., report at the North American Association for the Study of Obesity Oct. 11-15 in Ft. Lauderdale. Forty-four men and 86 women were provided with meal plans and diet plan instructions were followed for 10 years. At the study's conclusion, "the weight change from baseline was - 3.1 ± kg for men and - 2.4 ± kg for women, researchers report, adding matched controls gained roughly 12.1 kg over the same time period. The positive study results may alleviate 1FTC's stance that consumers should "be skeptical about products that claim they will keep weight off you permanently." Three other studies presented at the conference similarly touted Slim Fast's benefits...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.
As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.
Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.
